All In Biotech

Drug Trial Radar · NCT03270059

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

41

Actual

Start

Oct 6, 2017

Primary completion

Dec 15, 2027

Study completion Dec 15, 2028

Sponsor

Lead sponsor
OHSU Knight Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Celgene Corporation; Oregon Health and Science University
First posted
Sep 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.

Conditions

  • Central Nervous System Neoplasm
  • Cranial Nerve Disorder
  • Metastatic Malignant Neoplasm in the Brain

Interventions

  • FerumoxytolDrug

    Given IV

  • GadoliniumDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visualization of normal vasculatureTime frame: Up to 5 years
  2. Visualization of abnormal vasculatureTime frame: Up to 5 years
  3. Visualization of normal anatomical structuresTime frame: Up to 5 years
  4. Identification of the lesion corresponding areas on cerebral blood volume (CBV) mapsTime frame: Up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • OHSU Knight Cancer Institute

    Portland, Oregon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.